Cassano G B, Carrara S, Castrogiovanni P
Pharmakopsychiatr Neuropsychopharmakol. 1975 Jan;8(1):1-7. doi: 10.1055/s-0028-1094438.
A double blind between-groups trial was carried out to compare the effectiveness of the new benzodiazepine compound, bromazepam, (Lexotan, Ro 5-3350) as an anti-anxiety compound with that of diazepan. The fifty-eight psychoneurotic inpatients admitted to the trial were divided into two groups, "obsessives" and "neurotics", in order to assess any specific action of the drug. Assessment was made by means of B.P.R.S. of Overall and Gorham, R.S.A.S. of Hamilton, P.R.S. of Wittenborn and I.M.P.S. of Lorr. The results showed that bromazepam has a general therapeutic effectiveness (though not always as great as that of diazepam) as an anti-anxiety agent, while no difference in the effects of the two drugs was found between the two psychopathologic groups; with both treatments the "obsessives" responded less than the "neurotics". Detailed evaluation of the individual items of the I.M.P.S. showed that bromazepam is likely to exert a disinhibiting or "activating" action, unlike most other benzodiazepines in clinical use.
进行了一项双盲组间试验，以比较新型苯二氮䓬类化合物溴西泮（Lexotan，Ro 5 - 3350）作为抗焦虑化合物与地西泮的有效性。入选该试验的58名精神神经症住院患者被分为“强迫型”和“神经症型”两组，以便评估药物的任何特定作用。采用总体和戈尔曼的简明精神病评定量表（B.P.R.S.）、汉密尔顿的焦虑量表（R.S.A.S.）、维滕伯恩的精神病评定量表（P.R.S.）以及洛尔的住院病人多维度精神病量表（I.M.P.S.）进行评估。结果表明，溴西泮作为抗焦虑剂具有一般治疗效果（尽管并不总是与地西泮一样显著），而在两个精神病理组之间未发现两种药物的效果存在差异；两种治疗方法中，“强迫型”患者的反应均低于“神经症型”患者。对I.M.P.S.各项指标的详细评估表明，与大多数其他临床使用的苯二氮䓬类药物不同，溴西泮可能会产生去抑制或“激活”作用。
